MaxCyte, Inc. Exercise of options and PDMR dealing (1118Y)
December 29 2023 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 1118Y
MaxCyte, Inc.
29 December 2023
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, December 29, 2023: MaxCyte Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research,
announces that on 26 December 2023, as per a filing lodged with the
U.S. Securities and Exchange Commission, John Johnston, a
Non-Executive Director of the Company , exercised options over
5,000 shares of common stock of $0.01 of the Company ("Common
Stock") ("Exercise") in aggregate. The 5,000 new shares of Common
Stock were issued pursuant to the Company's existing its block
admission facility and were sold by John Johnston at a price range
between $4.455 and $4.585 per Common Stock ("Sale"). The sold
shares represent approximately 1.7% of John Johnston's total equity
and option holdings in the Company's stock capital,
respectively.
Following the Exercise and Sale, John Johnston holds 120,583
shares of Common Stock representing 0.1% of the issued stock
capital of the Company. Following the Exercise, John Johnston holds
a further 177,217 options over Common Stock.
The sales and option exercises were effected pursuant to a Rule
10b5-1 trading plan adopted by John Johnston on 28 March 2023
relating solely to the sale of shares acquired from exercise of
options that expire on 20 January 2030.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
ICR Consilium maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Johnston
--------------------------------- -------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- -------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name MaxCyte Inc.
--------------------------------- -------------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------------- -------------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the Common Stock of $0.01 each
financial instrument,
type of instrument
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
--------------------------------- -------------------------------------------
c) Price(s) and volume(s)
------------------------- -------------
Exercise Price(s) Volume(s)
------------------------- -------------
$2.142 5,000
------------------------- -------------
d) Aggregated information
- Aggregated volume 5,000
- Price $2.142
e) Date of the transaction 26 December 2023
--------------------------------- -------------------------------------------
f) Place of the transaction US Stock Exchange, Nasdaq
--------------------------------- -------------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Johnston
--------------------------------- --------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name MaxCyte Inc.
--------------------------------- --------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Common Stock of $0.01 each
financial instrument,
type of instrument
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
--------------------------------- --------------------------------------
c) Price(s) and volume(s)
--------------------- ------------
Exercise Price(s) Volume(s)
--------------------- ------------
$4.4550 51
--------------------- ------------
$4.4600 286
--------------------- ------------
$4.4700 195
--------------------- ------------
$4.4800 403
--------------------- ------------
$4.4900 196
--------------------- ------------
$4.5000 194
--------------------- ------------
$4.5150 198
--------------------- ------------
$4.5200 294
--------------------- ------------
$4.5300 88
--------------------- ------------
$4.5350 321
--------------------- ------------
$4.5450 195
--------------------- ------------
$4.5500 588
--------------------- ------------
$4.5550 195
--------------------- ------------
$4.5600 878
--------------------- ------------
$4.5650 100
--------------------- ------------
$4.5700 518
--------------------- ------------
$4.5850 300
--------------------- ------------
d) Aggregated information
- Aggregated volume 5,000
- Price $4.5326
e) Date of the transaction 26 December 2023
--------------------------------- --------------------------------------
f) Place of the transaction US Stock Exchange, Nasdaq
--------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTPBFTMTBTBJJ
(END) Dow Jones Newswires
December 29, 2023 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024
